Sunday 26 March 2023 - 11:45
In Business 43 Years - Since 1980
Sale: 25% Off !!
For Online Shopping Cart Orders Only
In-Stock Sizes Only - Limited Time Only
See Check-out Page For Further Details
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
Search:
P-8900 PLX4720, Free Base, >99%
- Size
- US $
- €
- £
- ¥
- 10 mg
- 44
- 40
- 35
- 5,800
- In stock
- 25 mg
- 65
- 60
- 53
- 8,500
- In stock
- 50 mg
- 94
- 87
- 76
- 12,300
- In stock
- 100 mg
- 134
- 124
- 109
- 17,500
- In stock
- 200 mg
- 186
- 172
- 152
- 24,300
- In stock
- 500 mg
- 330
- 306
- 269
- 43,100
- In stock
- 1 g
- 529
- 490
- 432
- 69,200
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities
Free Shipping and Handling to the U.S. and 32 Other Countries
- M.W. 413.83
- C17H14ClF2N3O3S
- [918505-84-7]
Solubility: DMSO.
- PLX4720 is a kinase inhibitor with marked selectivity against B-Raf(V600E), with an IC50 of 13 nM. PLX4720 induced cell cycle arrest and apoptosis exclusively in B-Raf(V600E)-positive cells in melanoma models. In B-Raf(V600E)-dependent tumor xenograft models, PLX4720 caused significant tumor growth delays without evidence of toxicity. Tsai J., et al. "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity." Proc. Natl. Acad. Sci. USA 105: 3041-3046 (2008).
- PLX4720 induced significant tumor regression and reversal of cachexia in an orthotopic mouse model of human anaplastic thyroid cancer that harbored the BRAF(V600E) mutation. Nehs M.A., et al. "Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer." Endocrinology 153: 985-994 (2012).
- Resistance to BRAF inhibition by PLX4720 in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents in vitro and in vivo. Mao M., et al. "Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents." Clin. Cancer Res. 19: 657-667 (2013).
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
